<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39552875</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2072-1439</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>31</Day></PubDate></JournalIssue><Title>Journal of thoracic disease</Title><ISOAbbreviation>J Thorac Dis</ISOAbbreviation></Journal><ArticleTitle>Anticoagulant therapy in adult with COVID-19: a systematic review and meta-analysis of randomized controlled trial.</ArticleTitle><Pagination><StartPage>6391</StartPage><EndPage>6405</EndPage><MedlinePgn>6391-6405</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.21037/jtd-24-744</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Blood coagulation dysfunction is a risk factor for adverse outcomes in patients with coronavirus disease 2019 (COVID-19), especially in severe cases. The evidence for the effects of anticoagulation therapy on prognosis of COVID-19 patients and its risk of causing bleeding events is accumulating. Here we conducted a meta-analysis to assess the efficacy and safety of anticoagulants in COVID-19 patients of different severity.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We searched PubMed, Embase databases, Cochrane Trials, OVID MEDLINE from December 2019 to April 2023. We included randomized controlled trials (RCTs) involving COVID-19 patients over 18 years of age, which explored the effect of anticoagulant and its dose on outcomes including all-cause mortality, bleeding events or thrombotic events. We calculated the risk ratio (RR) and its 95% confidence interval (CI) for each outcome. We also performed subgroup analyses to assess the impact of disease severity, using a fixed-effect model to test for heterogeneity. The risk of bias, publication bias, and the quality of evidence were also evaluated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A total of 20 RCTs were included for final analysis. When compared with standard care, anticoagulation treatment reduced all-cause mortality (RR 0.47, 95% CI: 0.29-0.76) and thrombotic events (RR 0.35, 95% CI: 0.15-0.83) in the whole population with COVID-19 (n=2,365), without increase in bleeding events (total: RR 1.47, 95% CI: 0.54-4.00). Most of the studies only enrolled non-severe patients (n=2,329), while the number of severe patients (n=36) was scarce. In RCTs compared therapeutical and prophylactic doses of anticoagulants, no significant difference in on all-cause mortality was found in the whole population and non-severe and severe subgroups (total: RR 1.01, 95% CI: 0.92-1.10; non-severe: RR 1.03, 95% CI: 0.81-1.32; severe: RR 1.00, 95% CI: 0.91-1.11). Therapeutical dose reduced risk of thrombotic events (total: RR 0.59, 95% CI: 0.48-0.73; subtotal of non-severe: RR 0.57, 95% CI: 0.39-0.84; Subtotal of severe: RR 0.61, 95% CI: 0.47-0.78), while risk of bleeding was increased (total: RR 1.98, 95% CI: 1.47-2.66; non-severe: RR 2.38, 95% CI: 1.56-3.62; severe: RR 1.63, 95% CI: 1.07-2.47). Study heterogeneity was found only in the analysis of effects of anticoagulants on risk of thrombotic events.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Anticoagulant therapy reduces all-cause mortality and risk of thrombosis in non-severe COVID-19 patients. Therapeutic dose of anticoagulant therapy can be considered in both non-severe and severe COVID-19 patients to reduce thrombosis, but may be associated with increased bleeding events.</AbstractText><CopyrightInformation>2024 AME Publishing Company. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhou</LastName><ForeName>Yanan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Yang</LastName><ForeName>Yanping</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hou</LastName><ForeName>Dongni</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Shanghai Key Laboratory of Lung Inflammation and Injury, Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Yuanlin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shanghai Key Laboratory of Lung Inflammation and Injury, Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shanghai Respiratory Research Institute, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National and Shanghai Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Chemical Injury, Emergency and Critical Medicine of Shanghai Municipal Health Commission, Center of Emergency and Critical Medicine, Jinshan Hospital of Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>J Thorac Dis</MedlineTA><NlmUniqueID>101533916</NlmUniqueID><ISSNLinking>2072-1439</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anticoagulant therapy</Keyword><Keyword MajorTopicYN="N">all-cause mortality</Keyword><Keyword MajorTopicYN="N">bleeding events</Keyword><Keyword MajorTopicYN="N">coronavirus disease 2019 (COVID-19)</Keyword><Keyword MajorTopicYN="N">thromboses</Keyword></KeywordList><CoiStatement>Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-24-744/coif). Y.W. receives National Natural Science Foundation of China (82200090). Y.S. receives funding from Shanghai Municipal Science and Technology Major Project (ZD2021CY001), National Natural Science Foundation of China (82130001, 82272243), Science and Technology Commission of Shanghai Municipality (20Z11901000, 20DZ2261200, 20XD1401200, 22Y11900800), Clinical Research Plan of SHDC (SHDC2020CR5010-002), Shanghai Municipal Key Clinical Specialty (shslczdzk02201) and Shanghai Municipal Health Commission and Shanghai Municipal Administrator of Traditional Chinese Medicine [ZY(2021-2023)-0207-01]. The other authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>18</Day><Hour>5</Hour><Minute>57</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39552875</ArticleId><ArticleId IdType="pmc">PMC11565368</ArticleId><ArticleId IdType="doi">10.21037/jtd-24-744</ArticleId><ArticleId IdType="pii">jtd-16-10-6391</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Coronavirus disease (COVID-19) Epidemiological Updates and Monthly Operational Updates. Available online: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports</Citation></Reference><Reference><Citation>Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020;46:846-8. 10.1007/s00134-020-05991-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-020-05991-x</ArticleId><ArticleId IdType="pmc">PMC7080116</ArticleId><ArticleId IdType="pubmed">32125452</ArticleId></ArticleIdList></Reference><Reference><Citation>Zella D, Giovanetti M, Cella E, et al. The importance of genomic analysis in cracking the coronavirus pandemic. Expert Rev Mol Diagn 2021;21:547-62. 10.1080/14737159.2021.1917998</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14737159.2021.1917998</ArticleId><ArticleId IdType="pmc">PMC8095159</ArticleId><ArticleId IdType="pubmed">33849359</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiersinga WJ, Rhodes A, Cheng AC, et al. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA 2020;324:782-93. 10.1001/jama.2020.12839</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12839</ArticleId><ArticleId IdType="pubmed">32648899</ArticleId></ArticleIdList></Reference><Reference><Citation>Tammaro A, Adebanjo GAR, Del Nonno F, et al. Cutaneous Endothelial Dysfunction and Complement Deposition in COVID-19. Am J Dermatopathol 2021;43:237-8. 10.1097/DAD.0000000000001825</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/DAD.0000000000001825</ArticleId><ArticleId IdType="pubmed">33055532</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustine JN, Jones D. Immunopathology of Hyperinflammation in COVID-19. Am J Pathol 2021;191:4-17. 10.1016/j.ajpath.2020.08.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2020.08.009</ArticleId><ArticleId IdType="pmc">PMC7484812</ArticleId><ArticleId IdType="pubmed">32919977</ArticleId></ArticleIdList></Reference><Reference><Citation>Sastry S, Cuomo F, Muthusamy J. COVID-19 and thrombosis: The role of hemodynamics. Thromb Res 2022;212:51-7. 10.1016/j.thromres.2022.02.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2022.02.016</ArticleId><ArticleId IdType="pmc">PMC8864963</ArticleId><ArticleId IdType="pubmed">35219932</ArticleId></ArticleIdList></Reference><Reference><Citation>Klok FA, Kruip MJHA, van der Meer NJM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. Thromb Res 2020;191:148-50. 10.1016/j.thromres.2020.04.041</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2020.04.041</ArticleId><ArticleId IdType="pmc">PMC7192101</ArticleId><ArticleId IdType="pubmed">32381264</ArticleId></ArticleIdList></Reference><Reference><Citation>Diagnosis and Treatment Protocol for Novel Coronavirus Infection (Trial version 10). Available online: https://www.gov.cn/zhengce/zhengceku/2023-01/06/content_5735343.htm</Citation></Reference><Reference><Citation>Available online: https://www.covid19treatmentguidelines.nih.gov/</Citation></Reference><Reference><Citation>Schulman S, Sholzberg M, Spyropoulos AC, et al. ISTH guidelines for antithrombotic treatment in COVID-19. J Thromb Haemost 2022;20:2214-25. 10.1111/jth.15808</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15808</ArticleId><ArticleId IdType="pmc">PMC9349907</ArticleId><ArticleId IdType="pubmed">35906716</ArticleId></ArticleIdList></Reference><Reference><Citation>ATTACC Investigators ; ACTIV-4a Investigators; REMAP-CAP Investigators, et al. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. N Engl J Med 2021;385:790-802. 10.1056/NEJMoa2105911</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2105911</ArticleId><ArticleId IdType="pmc">PMC8362594</ArticleId><ArticleId IdType="pubmed">34351721</ArticleId></ArticleIdList></Reference><Reference><Citation>Sholzberg M, Tang GH, Rahhal H, et al. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. BMJ 2021;375:n2400. 10.1136/bmj.n2400</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n2400</ArticleId><ArticleId IdType="pmc">PMC8515466</ArticleId><ArticleId IdType="pubmed">34649864</ArticleId></ArticleIdList></Reference><Reference><Citation>Spyropoulos AC, Goldin M, Giannis D, et al. Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial. JAMA Intern Med 2021;181:1612-20. Erratum in: JAMA Intern Med 2022;182:239. 10.1001/jamainternmed.2021.6203</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2021.6203</ArticleId><ArticleId IdType="pmc">PMC8498934</ArticleId><ArticleId IdType="pubmed">34617959</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopes RD, de Barros E, Silva PGM, Furtado RHM, et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet 2021;397:2253-63. 10.1016/S0140-6736(21)01203-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01203-4</ArticleId><ArticleId IdType="pmc">PMC8177770</ArticleId><ArticleId IdType="pubmed">34097856</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone GW, Farkouh ME, Lala A, et al. Randomized Trial of Anticoagulation Strategies for Noncritically Ill Patients Hospitalized With COVID-19. J Am Coll Cardiol 2023;81:1747-62. 10.1016/j.jacc.2023.02.041</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2023.02.041</ArticleId><ArticleId IdType="pmc">PMC9987252</ArticleId><ArticleId IdType="pubmed">36889611</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasuda H, Mayumi T, Okano H. Efficacy of different anticoagulant doses for patients with COVID-19: a systematic review and network meta-analysis. Infection 2022;50:1453-63. 10.1007/s15010-022-01809-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-022-01809-8</ArticleId><ArticleId IdType="pmc">PMC8966866</ArticleId><ArticleId IdType="pubmed">35355236</ArticleId></ArticleIdList></Reference><Reference><Citation>Giossi R, Menichelli D, Pani A, et al. A Systematic Review and a Meta-Analysis Comparing Prophylactic and Therapeutic Low Molecular Weight Heparins for Mortality Reduction in 32,688 COVID-19 Patients. Front Pharmacol 2021;12:698008. 10.3389/fphar.2021.698008</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.698008</ArticleId><ArticleId IdType="pmc">PMC8443784</ArticleId><ArticleId IdType="pubmed">34539396</ArticleId></ArticleIdList></Reference><Reference><Citation>Parisi R, Costanzo S, Di Castelnuovo A, et al. Different Anticoagulant Regimens, Mortality, and Bleeding in Hospitalized Patients with COVID-19: A Systematic Review and an Updated Meta-Analysis. Semin Thromb Hemost 2021;47:372-91. 10.1055/s-0041-1726034</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0041-1726034</ArticleId><ArticleId IdType="pubmed">33851386</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamel AM, Sobhy M, Magdy N, et al. Anticoagulation outcomes in hospitalized Covid-19 patients: A systematic review and meta-analysis of case-control and cohort studies. Rev Med Virol 2021;31:e2180. 10.1002/rmv.2180</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2180</ArticleId><ArticleId IdType="pmc">PMC7646049</ArticleId><ArticleId IdType="pubmed">33022834</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu YF, Pan LY, Zhang WW, et al. A meta-analysis of the incidence of venous thromboembolic events and impact of anticoagulation on mortality in patients with COVID-19. Int J Infect Dis 2020;100:34-41. 10.1016/j.ijid.2020.08.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.08.023</ArticleId><ArticleId IdType="pmc">PMC7425668</ArticleId><ArticleId IdType="pubmed">32798659</ArticleId></ArticleIdList></Reference><Reference><Citation>REMAP-CAP Investigators ; ACTIV-4a Investigators; ATTACC Investigators, et al. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. N Engl J Med 2021;385:777-89. 10.1056/NEJMoa2103417</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2103417</ArticleId><ArticleId IdType="pmc">PMC8362592</ArticleId><ArticleId IdType="pubmed">34351722</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928. 10.1136/bmj.d5928</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.d5928</ArticleId><ArticleId IdType="pmc">PMC3196245</ArticleId><ArticleId IdType="pubmed">22008217</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne JA, Sutton AJ, Ioannidis JP, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011;343:d4002. 10.1136/bmj.d4002</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.d4002</ArticleId><ArticleId IdType="pubmed">21784880</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendoza C, Kraemer P, Herrera P, et al. Clinical guidelines using the GRADE system (Grading of Recommendations Assessment, Development and Evaluation). Rev Med Chil 2017;145:1463-70. 10.4067/s0034-98872017001101463</Citation><ArticleIdList><ArticleId IdType="doi">10.4067/s0034-98872017001101463</ArticleId><ArticleId IdType="pubmed">29664529</ArticleId></ArticleIdList></Reference><Reference><Citation>Reis S, Popp M, Schießer S, et al. Anticoagulation in COVID-19 patients - An updated systematic review and meta-analysis. Thromb Res 2022;219:40-8. 10.1016/j.thromres.2022.09.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2022.09.001</ArticleId><ArticleId IdType="pmc">PMC9451936</ArticleId><ArticleId IdType="pubmed">36113402</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaimes F, de la Rosa G. Anticoagulation and sepsis: the opportunity for a new use of heparin? Biomedica 2006;26:150-60. 10.7705/biomedica.v26i1.1404</Citation><ArticleIdList><ArticleId IdType="doi">10.7705/biomedica.v26i1.1404</ArticleId><ArticleId IdType="pubmed">16929913</ArticleId></ArticleIdList></Reference><Reference><Citation>Ananworanich J, Mogg R, Dunne MW, et al. Randomized Study of Rivaroxaban vs Placebo on Disease Progression and Symptoms Resolution in High-Risk Adults With Mild Coronavirus Disease 2019. Clin Infect Dis 2022;75:e473-81. 10.1093/cid/ciab813</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab813</ArticleId><ArticleId IdType="pmc">PMC8522357</ArticleId><ArticleId IdType="pubmed">34523673</ArticleId></ArticleIdList></Reference><Reference><Citation>Barco S, Voci D, Held U, et al. Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet Haematol 2022;9:e585-93. 10.1016/S2352-3026(22)00175-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3026(22)00175-2</ArticleId><ArticleId IdType="pmc">PMC9243568</ArticleId><ArticleId IdType="pubmed">35779558</ArticleId></ArticleIdList></Reference><Reference><Citation>Cools F, Virdone S, Sawhney J, et al. Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial. Lancet Haematol 2022;9:e594-604. 10.1016/S2352-3026(22)00173-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3026(22)00173-9</ArticleId><ArticleId IdType="pmc">PMC9243570</ArticleId><ArticleId IdType="pubmed">35779560</ArticleId></ArticleIdList></Reference><Reference><Citation>DeNucci G, Wilkinson T, Sverdloff C, et al. Inhaled nebulised unfractionated heparin (UFH) for the treatment of hospitalised patients with COVID-19: A randomised controlled pilot study. Pulm Pharmacol Ther 2023;80:102212. 10.1016/j.pupt.2023.102212</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pupt.2023.102212</ArticleId><ArticleId IdType="pmc">PMC10064078</ArticleId><ArticleId IdType="pubmed">36990381</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramacciotti E, Barile Agati L, Calderaro D, et al. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. Lancet 2022;399:50-9. 10.1016/S0140-6736(21)02392-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)02392-8</ArticleId><ArticleId IdType="pmc">PMC8673881</ArticleId><ArticleId IdType="pubmed">34921756</ArticleId></ArticleIdList></Reference><Reference><Citation>Toshner M R, Gamble C, Baillie J K, et al. Apixaban following discharge in hospitalised adults with COVID-19: Preliminary results from a multicentre, open-label, randomised controlled platform clinical trial (M/OL). medRxiv, 2022:2022.12.07.22283175 (2023-05-07).</Citation></Reference><Reference><Citation>Barrett CD, Moore HB, Moore EE, et al. Study of Alteplase for Respiratory Failure in SARS-CoV-2 COVID-19: A Vanguard Multicenter, Rapidly Adaptive, Pragmatic, Randomized Controlled Trial. Chest 2022;161:710-27. 10.1016/j.chest.2021.09.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2021.09.024</ArticleId><ArticleId IdType="pmc">PMC8474873</ArticleId><ArticleId IdType="pubmed">34592318</ArticleId></ArticleIdList></Reference><Reference><Citation>Connors JM, Brooks MM, Sciurba FC, et al. Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial. JAMA 2021;326:1703-12. 10.1001/jama.2021.17272</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.17272</ArticleId><ArticleId IdType="pmc">PMC8506296</ArticleId><ArticleId IdType="pubmed">34633405</ArticleId></ArticleIdList></Reference><Reference><Citation>ATTACC Investigators ; ACTIV-4a Investigators; REMAP-CAP Investigators, et al. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. N Engl J Med 2021;385:790-802. 10.1056/NEJMoa2105911</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2105911</ArticleId><ArticleId IdType="pmc">PMC8362594</ArticleId><ArticleId IdType="pubmed">34351721</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcos-Jubilar M, Carmona-Torre F, Vidal R, et al. Therapeutic versus Prophylactic Bemiparin in Hospitalized Patients with Nonsevere COVID-19 Pneumonia (BEMICOP Study): An Open-Label, Multicenter, Randomized, Controlled Trial. Thromb Haemost 2022;122:295-9. 10.1055/a-1667-7534</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/a-1667-7534</ArticleId><ArticleId IdType="pubmed">34638151</ArticleId></ArticleIdList></Reference><Reference><Citation>Morici N, Podda G, Birocchi S, et al. Enoxaparin for thromboprophylaxis in hospitalized COVID-19 patients: The X-COVID-19 Randomized Trial. Eur J Clin Invest 2022;52:e13735. 10.1111/eci.13735</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/eci.13735</ArticleId><ArticleId IdType="pubmed">34958123</ArticleId></ArticleIdList></Reference><Reference><Citation>Bikdeli B, Talasaz AH, Rashidi F, et al. Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial. Thromb Haemost 2022;122:131-41. 10.1055/a-1485-2372</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/a-1485-2372</ArticleId><ArticleId IdType="pubmed">33865239</ArticleId></ArticleIdList></Reference><Reference><Citation>Labbé V, Contou D, Heming N, et al. Effects of Standard-Dose Prophylactic, High-Dose Prophylactic, and Therapeutic Anticoagulation in Patients With Hypoxemic COVID-19 Pneumonia: The ANTICOVID Randomized Clinical Trial. JAMA Intern Med 2023;183:520-31. 10.1001/jamainternmed.2023.0456</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2023.0456</ArticleId><ArticleId IdType="pmc">PMC10034664</ArticleId><ArticleId IdType="pubmed">36946232</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemos ACB, do Espírito Santo DA, Salvetti MC, et al. Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID). Thromb Res 2020;196:359-66. 10.1016/j.thromres.2020.09.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2020.09.026</ArticleId><ArticleId IdType="pmc">PMC7503069</ArticleId><ArticleId IdType="pubmed">32977137</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliynyk O, Barg W, Slifirczyk A, et al. Comparison of the Effect of Unfractionated Heparin and Enoxaparin Sodium at Different Doses on the Course of COVID-19-Associated Coagulopathy. Life (Basel) 2021;11:1032. 10.3390/life11101032</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/life11101032</ArticleId><ArticleId IdType="pmc">PMC8537389</ArticleId><ArticleId IdType="pubmed">34685403</ArticleId></ArticleIdList></Reference><Reference><Citation>Perepu US, Chambers I, Wahab A, et al. Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: A multi-center, open-label, randomized controlled trial. J Thromb Haemost 2021;19:2225-34. 10.1111/jth.15450</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15450</ArticleId><ArticleId IdType="pmc">PMC8420176</ArticleId><ArticleId IdType="pubmed">34236768</ArticleId></ArticleIdList></Reference><Reference><Citation>INSPIRATION Investigators ; Sadeghipour P, Talasaz AH, et al. Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial. JAMA 2021;325:1620-30. 10.1001/jama.2021.4152</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.4152</ArticleId><ArticleId IdType="pmc">PMC7974835</ArticleId><ArticleId IdType="pubmed">33734299</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng J, Liu F, Wang Y, et al. The effect of previous oral anticoagulant use on clinical outcomes in COVID-19: A systematic review and meta-analysis. Am J Emerg Med 2022;54:107-10. 10.1016/j.ajem.2022.01.059</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajem.2022.01.059</ArticleId><ArticleId IdType="pmc">PMC8810267</ArticleId><ArticleId IdType="pubmed">35152118</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai MF, Guo ST, Ke YJ, et al. The Use of Oral Anticoagulation Is Not Associated With a Reduced Risk of Mortality in Patients With COVID-19: A Systematic Review and Meta-Analysis of Cohort Studies. Front Pharmacol 2022;13:781192. 10.3389/fphar.2022.781192</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.781192</ArticleId><ArticleId IdType="pmc">PMC9008218</ArticleId><ArticleId IdType="pubmed">35431952</ArticleId></ArticleIdList></Reference><Reference><Citation>Tunjungputri RN, Tetrasiwi EN, Mulansari NA, et al. Parenteral and Oral Anticoagulant Treatment for Hospitalized and Post-Discharge COVID-19 Patients: A Systematic Review and Meta-Analysis. Acta Med Indones 2022;54:190-209.</Citation><ArticleIdList><ArticleId IdType="pubmed">35818663</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Nawawy AA, Elshinawy MI, Khater DM, et al. Outcome of Early Hemostatic Intervention in Children With Sepsis and Nonovert Disseminated Intravascular Coagulation Admitted to PICU: A Randomized Controlled Trial. Pediatr Crit Care Med 2021;22:e168-77. 10.1097/PCC.0000000000002578</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0000000000002578</ArticleId><ArticleId IdType="pubmed">33044411</ArticleId></ArticleIdList></Reference><Reference><Citation>Derhaschnig U, Reiter R, Knöbl P, et al. Recombinant human activated protein C (rhAPC; drotrecogin alfa [activated]) has minimal effect on markers of coagulation, fibrinolysis, and inflammation in acute human endotoxemia. Blood 2003;102:2093-8. 10.1182/blood-2003-02-0416</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2003-02-0416</ArticleId><ArticleId IdType="pubmed">12750166</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasuda N, Goto K, Ohchi Y, et al. The efficacy and safety of antithrombin and recombinant human thrombomodulin combination therapy in patients with severe sepsis and disseminated intravascular coagulation. J Crit Care 2016;36:29-34. 10.1016/j.jcrc.2016.06.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcrc.2016.06.008</ArticleId><ArticleId IdType="pubmed">27546744</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasuda H, Mayumi T, Okano H. Efficacy of different anticoagulant doses for patients with COVID-19: a systematic review and network meta-analysis. Infection 2022;50:1453-63. 10.1007/s15010-022-01809-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-022-01809-8</ArticleId><ArticleId IdType="pmc">PMC8966866</ArticleId><ArticleId IdType="pubmed">35355236</ArticleId></ArticleIdList></Reference><Reference><Citation>Caguana-Vélez OA, Khilzi K, Piccari L, et al. Chronic Thromboembolic Pulmonary Hypertension after Pulmonary Embolism in SARS-CoV-2. Respiration 2024;103:79-87. 10.1159/000536064</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000536064</ArticleId><ArticleId IdType="pubmed">38325355</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba T, Helms J, Neal MD, et al. Mechanisms and management of the coagulopathy of trauma and sepsis: trauma-induced coagulopathy, sepsis-induced coagulopathy, and disseminated intravascular coagulation. J Thromb Haemost 2023;21:3360-70. 10.1016/j.jtha.2023.05.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtha.2023.05.028</ArticleId><ArticleId IdType="pmc">PMC10873124</ArticleId><ArticleId IdType="pubmed">37722532</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelouahed M, Yateem D, Fredericks S. FcγRIIa - dependent platelet activation identified in COVID-19 vaccine-induced immune thrombotic thrombocytopenia-, heparin-induced thrombocytopenia, streptokinase- and anisoylated plasminogen-streptokinase activator complex-induced platelet activation. Front Cardiovasc Med 2023;10:1282637. 10.3389/fcvm.2023.1282637</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2023.1282637</ArticleId><ArticleId IdType="pmc">PMC10684751</ArticleId><ArticleId IdType="pubmed">38034388</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>